Zacks Research Issues Pessimistic Outlook for TMO Earnings

Key Points

• Zacks Research has revised its Q2 2026 earnings per share estimate for Thermo Fisher Scientific from $6.01 to $5.92.
• Barclays and UBS Group have both increased their price targets for Thermo Fisher Scientific's stock, with UBS raising its target from $460.00 to $500.00.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43, to be paid on October 15, with an annualized yield of 0.4%.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research report issued to clients and investors on Wednesday, September 10th. Zacks Research analyst Team now forecasts that the medical research company will earn $5.92 per share for the quarter, down from their prior forecast of $6.01. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q4 2026 earnings at $6.51 EPS, FY2026 earnings at $24.13 EPS, Q2 2027 earnings at $7.11 EPS and FY2027 earnings at $27.13 EPS.

Other research analysts have also recently issued reports about the company. Barclays lifted their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Evercore ISI cut their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. UBS Group boosted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $589.38.

Thermo Fisher Scientific Trading Down 1.1%

Thermo Fisher Scientific stock opened at $477.03 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $623.77. The stock has a market capitalization of $180.13 billion, a PE ratio of 27.59, a price-to-earnings-growth ratio of 2.58 and a beta of 0.75. The business's fifty day moving average is $464.58 and its 200 day moving average is $452.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the firm posted $5.37 earnings per share. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $25,000. CBIZ Investment Advisory Services LLC grew its stake in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares in the last quarter. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter worth about $30,000. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $30,000. Finally, Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.